Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 6Gastrointestinal 2Other hematologic neoplasm 1Other 1Genitourinary 1CNS 1

Conditions

Hematologic Neoplasms 1

Interventions

Cytarabine 898Cyclophosphamide 893fludarabine 517venetoclax 475fludarabine phosphate 464Azacitidine 451Rituximab 418Methotrexate 414Etoposide 319Filgrastim 299Busulfan 295Dexamethasone 284Vincristine 280Daunorubicin 279Peripheral Blood Stem Cell Transplantation 257Whole-Body Irradiation 240Mycophenolic Acid 231Decitabine 228Granulocyte Colony-Stimulating Factor 225Tacrolimus 219Idarubicin 203Melphalan 201Imatinib Mesylate 195Cyclosporine 182Doxorubicin 176Radiotherapy 169Prednisone 160Mitoxantrone 160Lenalidomide 159Antilymphocyte Serum 154

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Duloxetine Hydrochloride × Other hematologic neoplasm × Clear all
NCT04560673 2025-12-31

Duloxetine and Neurofeedback Training for the Treatment of Chemotherapy Induced Peripheral Neuropathy

M.D. Anderson Cancer Center

Phase 2 Recruiting
380 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡